Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155251 | 0.97 | FFAR1 (0.32) | FFAR1 | |
| SCHEMBL3154597 | 0.83 | SYK (0.34) | L3MBTL1PRMT5 | |
| SCHEMBL5738609 | 0.79 | RAB9A (0.43) | PRMT5 | |
| SCHEMBL3151199 | 0.79 | MAPT (0.32) | L3MBTL1 | |
| SCHEMBL78358 | 0.78 | F10 (0.44) | — | |
| SCHEMBL3151232 | 0.78 | F10 (0.48) | — | |
| SCHEMBL3160025 | 0.78 | MAPT (0.36) | PRMT5 | |
| SCHEMBL3155843 | 0.77 | NOTUM (0.34) | — | |
| SCHEMBL3156175 | 0.76 | F10 (0.44) | — | |
| SCHEMBL3375924 | 0.76 | F10 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526132-B1 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1411932-B1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2099453-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-1937271-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | Bayer HealthCare AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1933841-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | Bayer HealthCare AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008052671-A2 | COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007042146-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG (DE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007039134-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003000256-A9 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2001047919-A9 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AG (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1261606-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | Bayer Aktiengesellschaft (DE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001047919-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |